69 reports of this reaction
1.5% of all METHYLENE BLUE reports
#14 most reported adverse reaction
VASOPLEGIA SYNDROME is the #14 most commonly reported adverse reaction for METHYLENE BLUE, manufactured by American Regent, Inc.. There are 69 FDA adverse event reports linking METHYLENE BLUE to VASOPLEGIA SYNDROME. This represents approximately 1.5% of all 4,684 adverse event reports for this drug.
METHYLENE BLUE has an overall safety score of 85 out of 100. Patients taking METHYLENE BLUE who experience vasoplegia syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VASOPLEGIA SYNDROME is a less commonly reported adverse event for METHYLENE BLUE, but still significant enough to appear in the safety profile.
In addition to vasoplegia syndrome, the following adverse reactions have been reported for METHYLENE BLUE:
VASOPLEGIA SYNDROME has been reported as an adverse event in 69 FDA reports for METHYLENE BLUE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VASOPLEGIA SYNDROME accounts for approximately 1.5% of all adverse event reports for METHYLENE BLUE, making it a notable side effect.
If you experience vasoplegia syndrome while taking METHYLENE BLUE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.